



# UNIVERSITÀ DI PARMA

## ARCHIVIO DELLA RICERCA

University of Parma Research Repository

Interaction of Skeletal and Left Ventricular Mass in Older Adults with Low Muscle Performance

This is the peer reviewed version of the following article:

*Original*

Interaction of Skeletal and Left Ventricular Mass in Older Adults with Low Muscle Performance / Giovanna, Pelà; Tagliaferri, Sara; Perrino, Felice; Bussolati, Giacomo; Longobucco, Yari; Zerbinati, Luna; Adorni, Elisa; Calvani, Riccardo; Cesari, Matteo; Cherubini, Antonio; Bernabei, Roberto; Di Bari, Mauro; Landi, Francesco; Marzetti, Emanuele; Lauretani, Fulvio; Maggio, Marcello Giuseppe. - In: JOURNAL OF THE AMERICAN GERIATRICS SOCIETY. - ISSN 0002-8614. - 69:1(2021), pp. 148-154. [10.1111/jgs.16812]

*Availability:*

This version is available at: 11381/2880339 since: 2021-10-26T13:49:29Z

*Publisher:*

Blackwell Publishing Inc.

*Published*

DOI:10.1111/jgs.16812

*Terms of use:*

openAccess

Anyone can freely access the full text of works made available as "Open Access". Works made available

*Publisher copyright*

(Article begins on next page)

## Interaction of skeletal and left ventricular mass in older adults with low muscle performance

Journal:	<i>Journal of the American Geriatrics Society</i>
Manuscript ID	JAGS-1236-CI-Jun-20.R1
Wiley - Manuscript type:	Clinical Investigation
Date Submitted by the Author:	n/a
Complete List of Authors:	<p>Pelà, Giovanna; University of Parma Department of Medicine and Surgery; University Hospital of Parma</p> <p>Tagliaferri, Sara ; University of Parma Department of Medicine and Surgery</p> <p>Perrino, Felice; University of Parma Department of Medicine and Surgery; University Hospital of Parma</p> <p>Bussolati, Giacomo; University of Parma Department of Medicine and Surgery; University Hospital of Parma</p> <p>Longobucco, Yari; University of Parma Department of Medicine and Surgery</p> <p>Zerbinati, Luna; University of Parma Department of Medicine and Surgery</p> <p>Adorni, Elisa; University of Parma Department of Medicine and Surgery</p> <p>Calvani, Riccardo; Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Department of Geriatrics, Neurosciences and Orthopedics; University Hospital Agostino Gemelli, Fondazione Policlinico Universitario</p> <p>Cesari, Matteo; University of Milan, Department of Clinical Sciences and Community Health ; La Fondazione IRCCS Ca' Granda Ospedale Maggiore di Milano Policlinico, UOSD Geriatria</p> <p>Cherubini, Antonio; INRCA-IRCCS, Geriatria, Accettazione Geriatrica e Centro di ricerca per l'invecchiamento</p> <p>Bernabei, Roberto; Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Department of Geriatrics, Neurosciences and Orthopedics; University Hospital Agostino Gemelli, Fondazione Policlinico Universitario</p> <p>Di Bari, Mauro; University of Florence, Department of Experimental and Clinical Medicine, Research Unit of Medicine of Aging; University Hospital Careggi, Unit of Geriatrics- Geriatric Intensive Care Unit, Department of Medicine and Geriatrics</p> <p>Landi, Francesco; Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Department of Geriatrics, Neurosciences and Orthopedics; University Hospital Agostino Gemelli, Fondazione Policlinico Universitario</p> <p>Marzetti, Emanuele; Università Cattolica del Sacro Cuore Facoltà di Medicina e Chirurgia, Department of Geriatrics, Neurosciences and Orthopedics; University Hospital Agostino Gemelli, Fondazione Policlinico Universitario</p> <p>Lauretani, Fulvio; University of Parma Department of Medicine and</p>

	Surgery; University Hospital of Parma Maggio, Marcello; University of Parma Department of Medicine and Surgery; University Hospital of Parma
Key Words:	Skeletal Muscle Mass, left ventricular mass, SPRINTT study, low physical performance



# Interaction of Skeletal and Left Ventricular Mass in older adults with low muscle performance

## Running Title: Left ventricular mass and Sarcopenia

Giovanna Maria Pelà, M.D., Ph.D.<sup>a,b</sup>, Sara Tagliaferri, Sc.D. Ph.D.<sup>a</sup>, Felice Perrino, M.D.<sup>a,b</sup>, Giacomo Bussolati, M.D.<sup>a,b</sup>, Yari Longobucco, D.S.N.<sup>a</sup>, Luna Zerbinati, D.S.N.<sup>a</sup>, Elisa Adorni, D.P.T.<sup>a</sup>, Riccardo Calvani Sc.D., Ph.D.<sup>c,d</sup>, Matteo Cesari, M.D., Ph.D.<sup>e,f</sup>, Antonio Cherubini, M.D., Ph.D.<sup>g</sup>, Roberto Bernabei, M.D.<sup>c,d</sup>, Mauro Di Bari, M.D.<sup>h,i</sup>, Francesco Landi, M.D., Ph.D.<sup>c,d</sup>, Emanuele Marzetti, M.D., Ph.D.<sup>c,d</sup>, Fulvio Lauretani, M.D.<sup>a,b,l</sup> and Marcello Maggio, M.D., Ph.D.<sup>a,b,l</sup>.

<sup>a</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy;

<sup>b</sup>University Hospital of Parma, Parma, Italy;

<sup>c</sup>Department of Geriatrics, Neurosciences and Orthopedics, Università Cattolica del Sacro Cuore, Rome, Italy;

<sup>d</sup>Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy;

<sup>e</sup>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;

<sup>f</sup>UOSD Geriatria, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;

<sup>g</sup>Geriatrics, Accettazione Geriatrica e Centro di ricerca per l’invecchiamento. IRCCS INRCA, Ancona, Italy;

<sup>h</sup>Research Unit of Medicine of Aging, Department of Clinical and Experimental Medicine, University of Florence, Firenze, Italy

<sup>i</sup>Unit of Geriatrics - Geriatrics Intensive Care Unit, Department of Medicine and Geriatrics, Careggi Hospital, Firenze, Italy.

<sup>l</sup>Geriatric Clinic Unit, University-Hospital of Parma, Parma, Italy.

**Address Correspondence to** Giovanna Pelà, Department of Medicine and Surgery, University of Parma, Italy and University Hospital of Parma, via Gramsci 14, 43100 Parma, Italy. *E-mail address:*

[giovanna.pela@unipr.it](mailto:giovanna.pela@unipr.it)

*Word count abstract: 289; Word count text: 2955; Tables: 3; Figure: 1.*

## IMPACT STATEMENT

Older patients with low skeletal muscle mass and physical performance are unique population at high risk of cardiovascular events. We demonstrated for the first time, in this specific population with low

multimorbidity, that left ventricular muscle mass and skeletal muscle mass were positively correlated independently of cardiac output, haemoglobin and body mass index. These findings underline the future need of evaluating and monitoring in parallel left ventricular mass and skeletal muscle mass after proactive interventions including nutrition counseling and resistance exercise. We certify that this work is confirmatory of recent novel clinical research. (Keng et al, JAGS 2019;67:2568-2573).

For Review Only

## **ABSTRACT**

**BACKGROUND:** It was recently hypothesized the existence of “cardiac-skeletal muscle axis”. However, the relationship between skeletal muscle mass (SMM) and left ventricular mass (LVM) has never been investigated in the specific group of older individuals with low skeletal mass and physical performance.

We tested this hypothesis in the SPRINT-T (Sarcopenia and Physical Frailty IN older people: multicomponent Treatment strategies Trial) population using LVM as independent variable and SMM as dependent variable.

**METHODS:** SMM was assessed by DEXA-scan and expressed as Appendicular Muscle Mass (ALM), LVM was estimated through echocardiography. Low ALM was defined according to Foundation for the National Institutes of Health Sarcopenia Project (FNIH) criteria, and Short Physical Performance Battery (SPPB) was used to assess physical performance.

**RESULTS:** The population consisted of 100 persons (33 men and 67 women), aged  $\geq 70$  years (mean age  $79 \pm 5$ ) with low ALM and SPPB ranged between 3 and 9 suggestive of physical frailty. Charlson Comorbidity Index median score was 0. Mean values of LVM were  $193 \pm 67$  (g), indexed LVM to body surface area (LVM/BSA)  $112 \pm 33$  (g/m<sup>2</sup>), and Cardiac Output (CO)  $65 \pm 19$  (l/min). ALM was strongly and positively correlated with LVM ( $r=0.54602$ ,  $p<.0001$ ), LVM/BSA ( $r=0.30761$ ,  $p<0.002$ ), CO ( $r=0.49621$ ,  $p<.0001$ ), BMI ( $r=0.52461$ ,  $p<.0001$ ), sex ( $r=0.77$ ,  $p<0.001$ ), fat mass ( $r=0.38977$ ,  $p<0.0001$ ) and Hb ( $r=0.26001$ ,  $p<0.01$ ). In the multivariate analysis, LVM ( $\beta$   $0.019 \pm 0.005$ ;  $p<0.0001$ ), CO ( $\beta$   $0.038 \pm 0.016$ ;  $p=0.019$ ), BMI ( $\beta$   $0.286 \pm 0.051$ ;  $p<0.0001$ ) and Hb ( $\beta$   $0.544 \pm 0.175$ ;  $p=0.0025$ ) remained associated to ALM.

**CONCLUSIONS:** In a sample of older persons with low muscle mass and physical performance, LVM was positively and significantly correlated with ALM, independently from blood pressure, physical activity, and other potential confounders. Future studies are needed to address the effect of interventions targeting LVM and SMM.

**Key words: skeletal muscle mass; left ventricular mass; low physical performance; SPRINTT study.**

For Review Only

## INTRODUCTION

Sarcopenia is considered a primarily age-dependent condition, frequently overlapped with physical frailty,<sup>1</sup> a geriatric syndrome characterized by reduced homeostatic reserve. Both these conditions expose the subject to an increased risk of adverse events, including impaired physical function and disability.<sup>2</sup>

Changes in skeletal muscle mass (SMM) have been associated with cardiovascular diseases.<sup>3-6</sup> In particular, in patients with heart failure, either with reduced or preserved ejection fraction, a loss of SMM contributes to the onset of fatigue and exercise intolerance. Observational studies have also evaluated the relationship between frailty and cardiac function and cardiovascular diseases.<sup>7-10</sup> Patients with physical frailty have a higher prevalence of cardiovascular diseases such as myocardial infarction, angina, and congestive heart failure than well-performing patients.<sup>10</sup> Furthermore, in those patients without a history of cardiovascular disease, frailty was associated with subclinical heart disease i.e., left ventricular hypertrophy (LVH), which is considered a form of preclinical organ damage associated with systolic and diastolic dysfunction.<sup>7-9</sup>

Moreover, it has been demonstrated that, after bed rest or inactivity - well-known risk factors for sarcopenia and physical impairment - cardiac atrophy occurs in both men and women suggesting a common regulation of heart and muscle mass.<sup>11-13</sup>

All these data suggest the utmost important interaction of sarcopenia with cardiac mass during aging. The existence of *cardiac- muscle axis* has been recently hypothesized in older Singapore subjects where a positive and significant relationship was found between skeletal and cardiac ventricular mass.<sup>14</sup> Additionally, although low skeletal muscle mass is considered the other side of the coin, physical impairment,<sup>2</sup> the combination of these conditions is not routinely assessed during daily clinical practice. Given the unique opportunity to assess a selected cohort of participants enrolled because of low ALM and score of SPPB in the range between 3 and 9 (proxy of physical frailty), we explored the relationship between LVM (independent variable) and SMM (dependent variable) in a group of individuals with these characteristics.



## METHODS

Data are from an ancillary study of the Sarcopenia and Physical Frailty IN older people: multi-component Treatment strategies (SPRINT-T) project,<sup>15</sup> a randomized control trial conducted in frail, sarcopenic older subjects aged 70 years and older, to demonstrate the effectiveness of a multicomponent (MCI) intervention based on physical activity, nutritional and technological intervention versus a healthy aging lifestyle education (HALE) program for the prevention of mobility disability.

Inclusion and Exclusion criteria for the Study were detailed elsewhere:<sup>16</sup>

- Men and women aged  $\geq 70$  years;
- SPPB score between 3 (included) and 9 (included);
- Ability to complete the 400-m walk test within 15 min without sitting down, help from another person, use of a walker, or stopping for more than 1 minute at a time;
- Presence of low muscle mass according to results from a Dual Energy X-Ray Absorptiometry (DEXA) scan. In agreement with the FNIIH report 32, low muscle mass will be defined as: Body mass index-adjusted appendicular lean mass (ALM; i.e., the sum of lean mass from both arms and legs):  $<0.789$  in men, and  $<0.512$  in women, OR ii. ALM  $<19.75$  kg in men and  $<15.02$  kg in women;
- Willingness to be randomised to either intervention group and to follow the study protocol.

Exclusion criteria:

- Unable or unwilling to provide informed consent or accept randomisation to either study group;
- Plans to relocate out of the study area within the next 2 years or plans to be out of the study area for more than 6 consecutive weeks in the next year;
- Residence in long-term care;
- Household member enrolled in the study;

- Current diagnosis of schizophrenia, other psychotic or bipolar disorder. Depression is not an exclusion criterion;
- Consumption of more than 14 alcoholic drinks per week;
- Difficulty communicating with the study personnel due to speech, language, or (noncorrected) hearing problems;
- Mini Mental State Examination (MMSE) lower than 24/30;
- Severe osteoarthritis (e.g., awaiting joint replacement) that would interfere with the ability to participate fully in either study arm;
- Cancer requiring treatment in the past 3 years, except for non-melanoma skin cancers or cancers that have an excellent prognosis (e.g., early stage breast or prostate cancer);
- Lung disease requiring regular use of supplemental oxygen;
- Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents;
- Severe cardiovascular disease (including New York Heart Association [NYHA] class III or IV. The investigators of the Parma SPRINT-T<sup>15-16</sup> site added, at the enrolment of participants, a complete cardiac assessment including clinical evaluation with 12-lead resting Electrocardiogram (ECG) and conventional and Doppler Tissue Echocardiographic (DTE) examination as part of the ancillary protocol to the enrolment of participants.

This ancillary study was submitted to SPRINT-T Scientific Committee and accepted by the Managing Entity, and subsequently approved by AVEN Local ethics committee (*Protocol n.10872*). Written informed consent was obtained from the participants.

One hundred subjects from those enrolled in the SPRINT-T study in the Frailty Clinic of the University-Hospital of Parma site were selected. Blood pressure (BP) and heart rate (HR) (OMRON 705 IT) were assessed with three consecutive measurements, the data of which were averaged.

Level of physical activity (PA) was assessed by a questionnaire that included detailed information on type, intensity and duration of physical activity.<sup>17</sup>

Whole-body DEXA scans were used to estimate SMM as ALM, and sarcopenia was defined according to the recommendation of the FNIH (ALM/BMI  $<0.789$  in men and  $<0.512$  in women; and/or crude ALM  $<19.75$  Kg in men and  $<15.02$  Kg in women).<sup>18</sup> Fat mass (FM) was also derived from DEXA and expressed in Kg.

Physical Frailty was assessed by SPPB, a battery of three tests with a score in the range between 3 and 9, and this was considered one of the eligibility criteria. Participants in the SPRINT-T trial needed to have sufficient cognitive abilities measured using MMSE, and those participants with MMSE  $> 24$  were included in the study.<sup>19</sup>

Charlson Comorbidity Index (CCI) was used to assess multimorbidity, the median score of CCI was estimated according to Charlson et al.<sup>20</sup>

M-mode, two-dimensional, and Doppler ECHO were performed by an ultrasonography-experienced cardiologist (GP), using a commercially available, multi-hertz sector, 2-4 MHz probe-equipped machine (Vivid S5, GE Healthcare, USA). The interventricular septal (SWT) and posterior (PWT) left ventricular (LV) wall thicknesses, systolic and diastolic (EDD) diameters and volumes, absolute LVM and indexed to body surface area (LVM/BSA) were calculated as previously described.<sup>21</sup> LVH was defined as LVM/BSA of  $>95\text{g}/\text{m}^2$  in women and  $>115\text{g}/\text{m}^2$  in men.<sup>22</sup> Relative wall thickness (RWT) was calculated as:  $(\text{SWT}+\text{PWT})/\text{EDD}$ , using the 0.42 cut-off to define eccentric ( $\leq 0.42$ ) or concentric ( $>0.42$ ) remodelling.<sup>22</sup> Simpson's biplane rule-based end-diastolic (EDV) and systolic (ESV) volumes and ejection fraction (EF) were calculated, while Fractional Shortening (FS) was:  $[(\text{EDV} - \text{ESV})/\text{EDV}] \times 100$ . Cardiac output was derived by the formula:  $\text{EDV}-\text{ESV}$ .

Mitral inflow pattern was analysed from apical 4-chamber view, and E and A wave and their ratio were considered as peak flow velocity (pv) and time velocity integral (tvi), in order to evaluate the conventional diastolic function. From the same projection, DTE analysis was performed at lateral site and postero-septum of mitral annulus to assess myocardial systolic (S) and diastolic (E', A') waves of LV. The ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus velocity (E/E' ratio) was calculated for the estimation of LV filling pressure.

DEXA scan and cardiological assessment were performed at baseline, within a temporal window of 30 days.

Data are reported as means±SD or numbers and percentage. Factors statistically correlated with ALM, proxy of SMM, were identified using age- and sex-adjusted partial correlation coefficient and Spearman partial rank–order correlation coefficients, as appropriate. Parsimonious models obtained by backward selection from initial fully adjusted models, including age, BMI, systolic BP (SBP), HR, LVM, CO, level of PA, Hb, MMSE and beta-blockers or ACE-inhibitors/angiotensin receptor blockers, were used to identify independent factors of ALM. Sex was not included in the model because the collinearity between LVM and sex ( $R=0.51$ ,  $p<0.0001$ ). A 2-tailed  $p$  value $<0.05$  was considered as statistically significant. SAS 8.2 statistical package was used for all analyses (SAS Institute, Inc., Cary, NC, USA).

## RESULTS

Table 1 shows the main characteristics of the study population: 67 were women and 33 men (mean age was  $79\pm 5$  years). The mean BMI was  $27.6$  Kg/m<sup>2</sup> with one third of the sample having BMI value  $>30$  Kg/m<sup>2</sup>. CCI median score was 0, without significant differences between men and women. The mean SBP value was  $138\pm 18$  mmHg and 70% had a history of hypertension; 12% had coronary artery disease, and 3% had significant cardiac valve disease. No sign of heart failure was detected in any of the patients. With regard to the other comorbidities of the sample, thyroid diseases were reported in 20% and diabetes mellitus in 9%. Forty-one percent of the participants were chronically on  $\beta$ -blockers, 32% on ACE-inhibitors, and 21% on Angiotensin II Receptor Blockers (ARB). Mean values of ALM crude and ALM/BMI and indexed by BMI and SPPB were consistent with the eligibility criteria adopted in SPRINT-T for defining a sarcopenic and physically frail population (Table 1).

The thicknesses of SWT and PW and the LV cavity size, as assessed by diameters and volumes, were in the normal range with males exhibiting greater LV thicknesses and dimensions compared

with females (Supplementary Table). Both LVM and LVM/BSA were higher in men and women, especially in older and hypertensive subjects with a tendency to a geometric remodelling, as evaluated by RWT in both groups (Supplementary Table).

LV systolic function, assessed by EF and FS, was in the normal range as well as CO in the total population, with females showing significantly lower CO and higher EF compared to the male group (Supplementary Table). The mitral inflow pattern showed significant reduction of the E/A ratios in these patients, suggesting an impaired relaxation, confirmed by a lower E' wave from DTE-analysis, which also demonstrated a reduction of S wave without significant differences between the male and female groups (Supplementary Table). E/E' excluded an increased LV filling pressure in our cohort.

ALM was strongly and positively correlated with LVM ( $r=0.54602$ ,  $p<.0001$ ), LVM/BSA ( $r=0.30761$ ,  $p<0.002$ ), CO ( $r=0.49621$ ,  $p<.0001$ ), but also with other structural cardiac parameters such as LV thicknesses, diameters, and volumes (Table 2). In addition, factors associated to ALM included BMI ( $r=0.52461$ ,  $p<.0001$ ), sex ( $r=0.77$ ,  $p<0.001$ ), FM ( $r=0.38977$ ,  $p<0.0001$ ) and Hb ( $r=0.26001$ ,  $p<0.01$ ) (Table 2). A negative association was detected between ALM and EF ( $r=-0.30$ ,  $p<.0001$ ) and FS ( $r=-0.27$ ,  $p<.001$ ), whilst no significant correlation was found with S wave and all diastolic parameters (E/A, E' wave and E/E'). Multivariate analysis confirmed as factors independently associated to ALM, only LVM ( $\beta 0.019\pm 0.005$ ;  $p<0.0001$ ), CO ( $\beta 0.038\pm 0.016$ ;  $p=0.019$ ), BMI ( $\beta 0.286 \pm 0.051$ ;  $p<0.0001$ ) and Hb ( $\beta 0.544 \pm 0.175$ ;  $p=0.0025$ ) (Table 3). Age, SBP, HR, levels of PA, pharmacological therapy, and MMSE were not significantly associated with ALM.

## DISCUSSION

Main results of the present study are the significant correlations between ALM, proxy of SMM, and LVM in older adults with low skeletal muscle mass and physical performance, independently by confounders. ALM was also associated with cardiac output, independently of LVM.

This relationship is not surprising. Sarcopenia shares with cardiovascular disease risk factors, such as age, sedentary lifestyle, obesity, insulin resistance, and metabolic syndrome.<sup>23,24</sup> Sarcopenia is also associated with an increased risk of cardiovascular diseases, as reported by the KNHANES survey.<sup>25</sup>

Recent studies have also shown that sarcopenia is strictly and independently associated with PWV and intima-media thickness, all risk factors of cardiovascular disease.<sup>26</sup>

The link between the cardiac disease and SMM is well-established in heart failure patients who develop secondary sarcopenia due to heart disease.<sup>3-6</sup> Reduced blood oxygenation, physical inactivity and associated increase of inflammatory markers, may induce damage in SMM and cardiac muscle mass.<sup>3-6</sup>

There are indeed few studies on the relationship between skeletal muscle disease, sarcopenia, and cardiac structure and function. We studied this relationship in a specific population of older persons selected because of low muscle mass and physical performance. Interestingly, we found a strong positive association between ALM and LVM and CO (functional and hemodynamic parameter), also independently of LVM (structural cardiac parameter) -i.e. more skeletal mass, more LVM and CO. Our data are consistent with Keng et coworkers who recently demonstrated, among a study sample of Asian older adults without cardiovascular disease, that sarcopenic participants (n=88 subjects aged 74) had smaller LV cavity size and mass than not sarcopenic ones, suggesting the presence of cardio-sarcopenia syndrome.<sup>14</sup> We confirmed this concept here in a different more characterized population (European vs Asian) of older individuals using a more robust technique of DEXA (instead of bioimpedance) to assess body composition.

These results are not in agreement with those presented in two previous studies.<sup>27,28</sup> The first study, conducted in a population of Koreans with an average age of 58 years enrolled in an

epidemiological study, showed that high visceral adiposity and low skeletal muscle mass were independent predictors of LVM.<sup>27</sup> However, the participants of this study were not classified according to sarcopenic status and were relatively young.

The second study, realized in a very large cohort of Korean adults (n=67,106), showed an increased prevalence of both diastolic dysfunction and LVH in the lowest skeletal muscle mass quartile.<sup>28</sup> In our cohort, ALM was positively correlated with LVM, and did not correlate with all diastolic indexes such as E/A, E' wave and E/E'. The different results can be explained by the fact that in the Korean study<sup>28</sup>, 70.7% of population attributed to Q1 group were obese (vs 39.0%, 20.7 and 7.1 in Q2, Q3 and Q4 respectively) with a higher proportion of hypertensive (23.1% vs 14.8, 11.6 and 7.7 in Q2, Q3 and Q4 respectively) and diabetic (8.4% vs 5.5, 3.8 and 2.5 in Q2, Q3 and Q4 respectively), well known factors that potentially influence negatively the diastolic function.

Our study is also different from the studies aforementioned for many reasons: the age of the population, ethnicity (Caucasian vs. Asian), and the homogeneity of our sample population, which included only older subjects with low SMM and physical performance.

We should also consider that high LVM is traditionally viewed as clinically unfavourable phenomenon and LVH in hypertensive pathology is associated with greater CV risk and poorer prognosis.<sup>29</sup> The higher incidence of CV, mainly coronary LVH-related events, is justified by the imbalance between increased consumption and insufficient O<sub>2</sub> intake available for increased demand. Conversely, it should be also underlined the potential role of LVH as a secondary compensatory mechanism adopted for increasing cardiac work. Examples in this regard include the physiological LVH of the athlete, i.e., the athlete's heart or pathological LVH occurring with the hypertensive heart or aortic stenosis.<sup>30,31</sup>

While physiological LVH allows an increase in cardiac output during sports performance, the pathological LVH ensures the maintenance of a normal cardiac throw, despite the increased after-load.<sup>30</sup> Pathological LVH, in contrast to the physiological one, is associated with both diastolic and

systolic dysfunction, which can be highlighted not with conventional functional indices, such as EF and FS, but with more sophisticated techniques such as DTE and Strain.<sup>32,33</sup>

Consistently, in our study ALM positively correlated with CO and this relationship was also maintained in the multivariate analysis, including LVM as covariate. We cannot exclude that the relationship between exposure and outcome (LVM and SMM) could have been influenced by multimorbidity. In our study sample, there were patients who had heart disease such as CAD, cardiac valve disease, as well as chronic conditions such as hypertension, COPD and thyroid disease. In total, these conditions may account for at least 40% of the study sample. In particular, the increased systolic BP and the high prevalence of hypertensive subjects (70%), could have contributed to increase LV mass; however, this hypothesis was not confirmed in the multivariate analysis.

Moreover, to better clarify the role of multimorbidity, we calculated crude CCI whose median score of 0 (not surprising given the strict exclusion criteria aforementioned), we evaluated the relationship between CCI and ALM, and the role of CCI in the association between ALM and LVM in the multivariate analysis. CCI was not a significant predictor of ALM ( $r=-0.12$ ,  $p=0.22$ ) and the introduction of CCI in the Backward Analysis did not change the significant relationship between ALM and LVM. Basing on this data, we can assume that multimorbidity had not a relevant impact in this specific sample.

We should acknowledge that our study has two main limitations including the limited number of subjects enrolled and the cross-sectional nature of this study that does not allow drawing conclusions about the nature of the relationship. Moreover, given the strict inclusion criteria and the cohort precisely defined features, the generalization of results for the entire population of the community of older adults deserves further investigation. Additionally, given the collinearity between sex and LVM, we cannot exclude an independent role of sex in determining ALM values. This should be verified in separate groups of males and females with a wider range of ALM values. The relatively low simple size of our group and the narrow dispersion of ALM in both



males and females cannot permit such an analysis and therefore it should be considered as a major limitation of the study.

However, these limitations are offset by important strengths. This is the first time a study investigates the relationship between ALM and LVM in a homogeneous group of both low muscle mass and physical performance. Furthermore, the echocardiographic examinations were performed by a single, experienced operator to limit the variability of the calculation of the LVM - a measure that is affected by both the quality of the images and the experience of the operator.

In conclusion, the present study is the first one that demonstrates a highly significant and positive relationship between ALM and LVM in a cohort of older adults with low muscle mass and physical performance. Our novel findings emphasize the need of studying skeletal and heart in tandem to better address the complexity of aging process.

## **ACKNOWLEDGEMENTS**

The authors would like to acknowledge Dr. Karen Elena Brothers, who critically revised the manuscript.

**Financial Disclosure:** The present work was funded by a grant from the Innovative Medicines Initiative - Joint Undertaking (IMI-JU 115621).

**Conflicts of interest:** None declared

**Author contributions:** GP, FL and MM contributed to the conception and design of the work. All authors contributed to the acquisition, analysis, or interpretation of data for the work. GP performed all echocardiographic examinations and drafted the manuscript. All authors critically revised the manuscript and gave final approval.

**Sponsor's role:** Some authors of the present work are partners of the SPRINTT consortium, which is partly funded by the European Federation of Pharmaceutical Industries and Associations (EFPIA).

## REFERENCES

1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al Sarcopenia: revised European consensus on definition and diagnosis. *Age Ageing* 2019;48(1):16–31. doi:10.1093/ageing/afy169.
2. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two sides of the same coin. *Front Aging Neurosci* 2014;6:192. doi:10.3389/fnagi.2014.00192.
3. Saitoh M, Ishida J, Doehner W, et al. Sarcopenia, cachexia, and muscle performance in heart failure: Review update 2016. *Int J Cardiol* 2017;238:5–11. doi:10.1016/j.ijcard.2017.03.155.
4. Adams V, Linke A, Winzer E. Skeletal muscle alterations in HF<sub>r</sub>EF vs. HF<sub>p</sub>EF. *Curr Heart Fail Rep* 2017;14:489-497. doi:10.1007/s11897-017-0361-9.
5. Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure-skeletal muscle dysfunction and potential therapies. *Circ J* 2013;77(2):293-300. doi:10.1253/circj.cj-12-123.
6. Seiler M, Bowen T S, Rolim N, et al. Skeletal Muscle Alterations Are Exacerbated in Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by Circulating Cytokines? *Circ Heart Fail* 2016;9(9):e003027. doi:10.1161/CIRCHEARTFAILURE.116.003027.
7. Gharacholou SM, Tashiro T, Cha SS, Scott CG, Takahashi PY, Pellikka PA. Echocardiographic indices associated with frailty in adults  $\geq 65$  years. *Am J Cardiol* 2015;116(10):1591–1595. doi:10.1016/j.amjcard.2015.08.023.
8. Leibowitz D, Jacobs JM, Gilon D, Lande-Stessman I, Ein-Mor E, Stessman J. Cardiac Structure and Function and Frailty in Subjects Aged 85 and 86 Years. *Am J Cardiol* 2016;118(5):760–764. doi:10.1016/j.amjcard.2016.06.005.
9. Nadruz W, Jr, Kitzman D, Windham B G, et al. Cardiovascular Dysfunction and Frailty Among Older Adults in the Community: The ARIC Study. *J Gerontol A Biol Sci Med Sci* 2017;72(7):958–964. doi:10.1093/gerona/glw199.

10. Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory meta-regression analysis. *Ageing Res Rev* 2017;35:63–73. doi:10.1016/j.arr.2017.01.003.
11. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on skeletal muscle in healthy older adults. *JAMA* 2007;297(16):1772–1774. doi:10.1001/jama.297.16.1772-b.
12. Perhonen M A, Franco F, Lane LD, et al. Cardiac atrophy after bed rest and spaceflight. *J Appl Physiol* 2001;91(2):645–653. doi:10.1152/jappl.2001.91.2.645.
13. Dorfman T A, Levine BD, Tillery T, et al. Cardiac atrophy in women following bed rest. *J Appl Physiol* 2007;103(1):8–16. doi:10.1152/jappphysiol.01162.2006.
14. Keng BMH, Gao F, Teo LLY, et al. Associations between Skeletal Muscle and Myocardium in aging: A syndrome of “Cardio-Sarcopenia”? *J Am Geriatr Soc* 2019;67:2568-2573. doi:10.1111/jgs.16132.
15. Marzetti E, Cesari M, Calvani R, et al. The "Sarcopenia and Physical fRaily IN older people: multi-component Treatment strategies" (SPRINTT) randomized controlled trial: Case finding, screening and characteristics of eligible participants. *Exp Gerontol* 2018;113:48–57. doi:10.1016/j.exger.2018.09.017.
16. Landi F, Cesari M, Calvani R, et al. The "Sarcopenia and Physical fRaily IN older people: multi-component Treatment strategies" (SPRINTT) randomized controlled trial: design and methods. *Aging Clin Exp Res* 2017;29(1):89–100. doi:10.1007/s40520-016-0715-2.
17. Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE. Validity and repeatability of the EPIC-Norfolk Physical Activity Questionnaire. *Int J Epidemiol* 2002;31:168–174. doi: 10.1093/ije/31.1.168.

18. Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale, study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci Med Sci* 2014;69(5):547–558. doi:10.1093/gerona/glu010.
19. Longobucco Y, Benedetti C, Tagliaferri S, et al. Proactive interception and care of Frailty and Multimorbidity in older persons: the experience of the European Innovation Partnership on Active and Healthy Ageing and the response of Parma Local Health Trust and Lab through European Projects. *Acta Biomed* 2019;90(2):364–374. doi:10.23750/abm.v90i2.8419.
20. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. *J Chronic Dis.* 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8.
21. Pelà G, Crocamo A, Li Calzi M, et al. Sex-related differences in left ventricular structure in early adolescent non-professional athletes. *Eur J Prev Cardiol* 2016;23(7):777–784. doi:10.1177/2047487315608826.
22. Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber quantification. *Eur J Echocardiogr* 2006;7(2):79–108. doi:10.1016/j.euje.2005.12.014.
23. Kang DO, Park SY, Choi BG, et al. Prognostic Impact of Low Skeletal Muscle Mass on Major Adverse Cardiovascular Events in Coronary Artery Disease: A Propensity Score-Matched Analysis of a Single Center All-Comer Cohort. *J Clin Med.* 2019;8(5):712. doi:10.3390/jcm8050712.
24. Bahat G, Ilhan B. Sarcopenia and cardiometabolic syndrome: A narrative review. *Eur Geriatric Med* 2016;7(3):220-223. doi:10.1016/j.eurger.2015.12.012..
25. Bieon CH, Kang KY, Kang SH, NiBae EJ. Sarcopenia is associated with Framingham risk score in the Korean population: Korean National Health and Nutrition examination survey (KNHANES). *J Geriatr Cardiol* 2015;12:366-372. doi:10.11909/j.issn.1671-5411.2015.04.007.

26. Ochi M, Kohara K, Tabara Y, et al. Arterial Stiffness is associated with low thigh muscle mass in middle-aged to elderly men. *Atherosclerosis* 2010;212(1):327–332. doi:10.1016/j.atherosclerosis.2010.05.026.
27. Park J, Kim NH, Kim SH, et al. Visceral adiposity and skeletal muscle mass are independently and synergistically associated with left ventricular structure and function: The Korean Genome and Epidemiology Study. *Int J Cardiol* 2014;176(3):951–955. doi:10.1016/j.ijcard.2014.08.108.
28. Ko BJ, Chang Y, Kang JG, et al. Low relative muscle mass and left ventricular diastolic dysfunction in middle-aged adults. *Int J Cardiol* 2018;255:118–123. doi:10.1016/j.ijcard.2017.07.089.
29. Levy D, Garrison RJ, Savage DD, Kannel WB, & Castelli WP. Prognostic Implications Of Echocardiographically Determined Left Ventricular Mass In The Framingham Heart Study. *N Engl J Med* 1990;322(22):1561–1566. doi:10.1056/NEJM199005313222203.
30. Lovic D, Narayan P, Pittaras A, Faselis C, Doumas M, Kokkinos P. Left ventricular hypertrophy in athletes and hypertensive patients. *J Clin Hypertens* 2017;19(4):413-417. doi:10.1056/NEJM199005313222203.
31. Rader F, Sachdev E, Arsanjani R, Siegel RJ. Left ventricular hypertrophy in valvular aortic stenosis: mechanisms and clinical implications. *Am J Med* 2015;128(4):344-352. doi:10.1016/j.amjmed.2014.10.054.
32. Pelà G, Bruschi G, Montagna L, Manara M, Manca C. Left and right ventricular adaptation assessed by Doppler tissue echocardiography in athletes. *J Am Soc Echocardiogr* 2004;17(3):205–211. doi:10.1016/j.echo.2003.12.004.
33. Pelà G, Bruschi G, Cavatorta A, Manca C, Cabassi A, Borghetti A. Doppler tissue echocardiography: myocardial wall motion velocities in essential hypertension. *Eur J Echocardiogr* 2001;2(2):108–117. doi:10.1053/euje.2000.0057.

## FIGURE LEGEND

Figure 1 is depicting the correlation between crude value of ALM and LVM (age- and sex-adjusted model).

For Review Only

1 **Table 1. Characteristics of CARDIO-SPRINTT population (N=100):**

VARIABLE	Total	Female	Male
Age (years)	79 ± 5	79 ± 5	80 ± 5
Female n, (%)	67 (67)	67	33
BMI (Kg/m <sup>2</sup> )	27.6 ± 5.1	27.5 ± 5.5	28.0 ± 4.3
Height (cm)	159 ± 8	155 ± 6	167 ± 7
Weight (Kg)	70 ± 15	65 ± 18	79 ± 13
HR (bpm)	66 ± 11	67 ± 12	65 ± 6
SBP (mmHg)	138 ± 18	138 ± 17	140 ± 20
DBP (mmHg)	80 ± 9	80 ± 9	79 ± 9
24h-SBP (mmHg)	129 ± 13	128 ± 10	130 ± 16
Hb (g/dl)	13.3 ± 1.4	13.0 ± 1.1	14.0 ± 1.9
Smoking n, (%)	8 (8)	4 (6)	4 (12)
Hypertension n, (%)	70 (70)	47 (70)	23 (70)
CAD n, (%)	12 (12)	3(4)	9 (27)
Cardiac valve disease n, (%)	3 (3)	3 (4)	-
COPD n, (%)	9 (9)	3 (4)	6 (18)
Diabetes mellitus	9 (9)	6 (9)	3 (9)
Obesity	30 (30)	20 (30)	10 (30)
Charlson Comorbidity Index, median , IQR	0 [0-1]	0[0-1]	1 [0-2]
Thyroid disease	20 (20)	19 (28)	1 (3)
Beta-Blockers n, (%)	41 (41)	26 (39)	15 (45)
Ace-Inhibitors n, (%)	32 (32)	21 (31)	11 (33)
ARB	21 (21)	14 (21)	7 (21)
ALM (Kg)	17.22 ± 3.73	15.23 ± 2.05	21.28 ± 3.02
ALM/BMI	0.62 ± 0.12	0.56 ± 0.08	0.76 ± 0.07
FM (Kg)	2.57 ± 0.85	2.53 ± 0.84	2.67 ± 0.86
SPPB	7.06 ± 1.2	7.15 ± 0.1	6.88 ± 1.56
MMSE	27.9 ± 1.7	27.9 ± 1.6	28.0 ± 1.8

2 Data are expressed as mean ± standard deviation or number of subjects with corresponding  
3 percentage [or Median and Interquartile Range \(IQR\)](#). ALM, appendicular lean mass; ALM/BMI,  
4 indexed appendicular lean mass; ARB, angiotensin receptor blocker; BMI, body mass index; CAD,  
5 coronary artery disease; COPD, chronic obstructive pulmonary disease; DBP, diastolic blood  
6 pressure; FM, Trunk Fat Mass; Hb, haemoglobin; HR, heart rate; MMSE, Mini Mental State  
7 Examination; SBP, systolic blood pressure; SPPB, short physical performance battery.

1 **Table 2. Factors related to Appendicular Lean Mass in All Subjects.**

Variable	Pearson's correlation r, (p-value)
<i>Clinical data</i>	
FM	0.39 (<0.001)
Age	-0.06 (0.23)
Sex	0.77 (<0.001)
BMI	0.52 (<0.001)
BSA	0.89 (<0.001)
SBP	-0.01 (0.21)
Hb	0.26 (<0.01)
SPPB	-0.06 (0.18)
HR	-0.10 (0.30)
MMSE	0.14 (0.15)
Ace-inhibitors	0.04 (0.72)*
B-blockers	0.24 (0.01)*
ARB	0.03 (0.70) *
Charlson Comorbidity Index	-0.12 (0.22)
<i>Structural LV data</i>	
LVM	0.55 (<0.001)
LVM/BSA	0.31 (0.002)
ESV	0.47 (<0.001)
EDV	0.54 (<0.001)
EDD	0.46(<0.001)
ESD	0.47 (<0.001)
SWT	0.35 (<0.001)
PW	0.34 (<0.001)
<i>Functional LV data</i>	
CO	0.50 (<0.001)
EF	-0.30 (<0.01)
FS	-0.27 (<0.01)
E/A pv	0.02 (0.32)
E/A tvi	0.13 (0.62)
DTE S pv sept.	0.11 (0.18)
DTE S pv lat.	-0.15 (0.25)
DTE E' pv sept.	0.08(0.22)
DTE E'pv lat.	-0.01 (0.27)
E/E'	-0.23 (0.70)

Footnotes: ARB, angiotensin receptor blocker; BMI: body mass index; BSA, body surface area; CO, cardiac output; DTE, Doppler tissue echocardiography; A', end-diastolic myocardial wave; E', proto-diastolic myocardial wave; S, systolic myocardial wave; pv, peak velocity; tvi, time velocity integral; EDD, end-diastolic diameter; EDV, end-diastolic volume; EF, ejection fraction; ESD, end-systolic diameter; ESV, end-systolic volume; FS, fractional shortening; LVM, left ventricular mass; ; MMSE, Mini Mental State Examination ; PW, posterior wall thickness; RWT, relative wall thickness; SWT, septal wall thickness;

2 \* using logistic regression analysis



1 **Table 3. Factors independently related to Appendicular Lean Mass.**

VARIABLE	$\beta \pm SE$	p-value
<b>LVM</b>	0.019 $\pm$ 0.005	<b>&lt;0.0001</b>
CO	0.038 $\pm$ 0.016	0.019
<b>BMI</b>	0.286 $\pm$ 0.051	<b>&lt;0.0001</b>
Haemoglobin	0.544 $\pm$ 0.175	0.0025


2 The full model obtained by Backward regression analysis included age, heart rate, Mini

3 Mental State Examination, Systolic Blood Pressure; Ace-inhibitors, betablockers, Mean level

4 of Physical Activity from 40 to 60 years old, **Charlson Comorbidity Index**.

For Review Only

\* age- and sex-adjusted



1 **Supplementary Table S1. Left ventricular structural and functional data in**  
 2 **CARDIO-SPRINTT Population (N=100)**

3

Variable	Total	Female	Male
EDD (mm)	46.6 ± 6.3	45.0 ± 5.4	49.9 ± 6.8
ESD (mm)	27.8 ± 6.2	26.2 ± 3.9	30.9 ± 8.5
SWT (mm)	9.7 ± 1.5	9.2 ± 1.2	10.6 ± 1.6
PW (mm)	9.3 ± 1.5	8.9 ± 1.3	10.0 ± 1.7
EDV (ml)	95 ± 31	87 ± 22	112 ± 40
ESV (ml)	30 ± 15.9	26 ± 8	38 ± 24
LVM (g)	193 ± 67	169 ± 45	241 ± 79
LVM/BSA	112 ± 33	104 ± 26	128 ± 39
LVH (%)	54 (54)	33 (58)	21 (64)
RWT	0.41 ± 0.07	0.41 ± 0.07	0.41 ± 0.06
FS (%)	40 ± 8	42 ± 6	39 ± 10
EF (%)	69 ± 7	70 ± 5	66 ± 10
CO (ml)	65 ± 19	61 ± 17	74 ± 21
Mitral E pv (cm/sec)	59 ± 17	60.1 ± 17	55.2 ± 15
Mitral E tvi (cm)	10.5 ± 3.1	10.5 ± 3.0	10.6 ± 3.4
Mitral A pv (cm/sec)	82 ± 19	84 ± 20	78 ± 16
Mitral A tvi (cm)	9.4 ± 2.7	9.8 ± 2.8	8.8 ± 2.5
Mitral E/Apv (cm/sec)	0.75 ± 0.35	0.76 ± 0.40	0.72 ± 0.21
Mitral E/A tvi (cm)	1.25 ± 0.93	1.15 ± 0.47	1.46 ± 1.49
DTE S pv (cm/sec)	8.12 ± 2.04	8.30 ± 1.90	7.77 ± 2.28
DTE S tvi (cm)	1.61 ± 0.35	1.65 ± 0.34	1.54 ± 0.37
DTE E' pv (cm/sec)	6.93 ± 2.14	7.11 ± 2.22	6.56 ± 1.97
DTE E' tvi (cm)	0.91 ± 0.14	0.88 ± 0.79	0.98 ± 1.63
DTE A' pv (cm/sec)	11.55 ± 2.93	11.34 ± 2.89	11.98 ± 2.99
DTE A' tvi (cm)	0.93 ± 0.23	0.92 ± 0.23	0.95 ± 0.24
DTE E'/A' pv	0.65 ± 0.37	0.69 ± 0.42	0.58 ± 0.22
DTE E'/A' tvi	1.01 ± 1.04	1.02 ± 0.94	0.99 ± 1.24
E/E'	9.9 ± 4.2	10.1 ± 4.4	9.5 ± 3.9

4 Data are expressed as mean ± standard deviation. BSA, body surface area; CO, cardiac output;  
 5 DTE, doppler tissue echocardiography; A', end-diastolic myocardial wave; E', proto-diastolic  
 6 myocardial wave; S, systolic myocardial wave; pv, peak velocity; tvi, time velocity integral;  
 7 EDD, end-diastolic diameter; EDV, end-diastolic volume; EF, ejection fraction; ESD, end-  
 8 systolic diameter; ESV, end-systolic volume; FS, fractional shortening; LVH, left ventricular  
 9 hypertrophy; LVM, left ventricular mass; ; PW, posterior wall thickness; RWT, relative wall  
 10 thickness; SWT, septal wall tickness. Values from DTE analysis are the mean of septal and  
 11 lateral walls.

1 **Relationship between Interaction of sSkeletal and LLeft Vventricular Mmass in**  
 2 **older adults with low physiealmuscle performance skeletal mass and left**  
 3 **ventricular mass in sarcopenic and frail older adults.**

4 **Running Title: Left ventricular mass and Sarcopenia**

5 **Giovanna Maria Pelà, M.D., Ph.D.,<sup>a,b</sup> Sara Tagliaferri, Sc.D. Ph.D.,<sup>a</sup> Felice Perrino, M.D.,<sup>a,b</sup>**  
 6 **Giacomo Bussolati, M.D.,<sup>a,b</sup> Yari Longobucco, D.S.N.,<sup>a</sup> Luna Zerbinati, D.S.N.,<sup>a</sup> Elisa**  
 7 **Adorni, D.P.T.,<sup>a</sup> Riccardo Calvani Sc.D., Ph.D.,<sup>c,d</sup> Matteo Cesari, M.D., Ph.D.,<sup>e,f</sup> Antonio**  
 8 **Cherubini, M.D., Ph.D.,<sup>g</sup> Roberto Bernabei, M.D.,<sup>c,d</sup> Mauro Di Bari, M.D.,<sup>h,i</sup> Francesco**  
 9 **Landi, M.D., Ph.D.,<sup>c,d</sup> Emanuele Marzetti, M.D., Ph.D.,<sup>c,d</sup> Fulvio Lauretani, M.D.,<sup>a,b,l</sup> and**  
 10 **Marcello Maggio, M.D, Ph.D.,<sup>a,b,l</sup>**

11

12 <sup>a</sup>Department of Medicine and Surgery, University of Parma, Parma, Italy;

13 <sup>b</sup>University Hospital of Parma, Parma, Italy;

14 <sup>c</sup>Department of Geriatrics, Neurosciences and Orthopedics, Università Cattolica del Sacro Cuore, Rome,  
 15 Italy;

16 <sup>d</sup>Fondazione Policlinico Universitario “Agostino Gemelli” IRCCS, Rome, Italy;

17 <sup>e</sup>Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy;

18 <sup>f</sup>UOSD Geriatria, Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milan, Italy;

19 <sup>g</sup>Geriatria, Accettazione Geriatrica e Centro di ricerca per l'invecchiamento. IRCCS INRCA, Ancona, Italy;

20 <sup>h</sup>Research Unit of Medicine of Aging, Department of Clinical and Experimental Medicine,  
 21 University of Florence, Firenze, Italy

22 <sup>i</sup>Unit of Geriatrics - Geriatrics Intensive Care Unit, Department of Medicine and Geriatrics, Careggi  
 23 Hospital, Firenze, Italy.

24 <sup>l</sup>Geriatric Clinic Unit, University-Hospital of Parma, Parma, Italy.

25

26 **Address Correspondence to** –Giovanna Pelà, Department of Medicine and Surgery, University of  
 27 Parma, Italy and University Hospital of Parma, via Gramsci 14, 43100 Parma, Italy. *E-mail address:*  
 28 [giovanna.pela@unipr.it](mailto:giovanna.pela@unipr.it)

29 *Word count abstract: 2889215; –Word count text: 279529255; Tables: 43; Figure: 1.*

30 **IMPACT STATEMENT**

31 ~~Frail and sarcopenic~~ Older patients ~~with~~ low skeletal muscle mass and physical performance are unique  
32 population at high risk of cardiovascular events. We demonstrated for the first time, in ~~–this specific~~  
33 ~~population with low multimorbidity, older frail and sarcopenic patients,~~ ~~t~~ that left ventricular muscle mass  
34 and skeletal muscle mass were positively correlated independently of cardiac output, haemoglobin and body  
35 mass index. These findings underline the ~~future~~ need of evaluating ~~and monitoring~~ in parallel left ventricular  
36 mass and skeletal muscle mass ~~and in the future their changes~~ after proactive interventions including  
37 nutrition counseling and ~~–~~resistance exercise. We certify that this work is ~~–~~confirmatory of recent novel  
38 clinical research. (Keng et al, JAGS 2019;67:2568-2573).

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 **ABSTRACT**

58 **BACKGROUND:** It was recently hypothesized the existence of “cardiac-skeletal muscle axis”.  
59 However, the~~No study has fully addressed the~~ relationship between skeletal muscle mass (SMM)  
60 and left ventricular mass (LVM) -has never been investigated in the specific group of of sarcopenic  
61 and frail older individuals with low skeletal mass and physical performances~~sarcopenic and frail~~  
62 older persons.

63 We tested this hypothesis in the SPRINT-T (Sarcopenia and Physical Frailty IN older people:  
64 multicomponent Treatment strategies Trial) population using ~~The aim of the present study was to~~  
65 evaluate the existence of “cardiac-skeletal muscle axis” assessing the relationship between LVM as  
66 (independent variable) and SMM as dependent variable~~in the SPRINT-T (Sarcopenia and Physical~~  
67 Frailty IN older people: multicomponent Treatment strategies Trial) population.

68 **METHODS:** ~~The population consisted of 100 persons (33 men and 67 women), aged  $\geq 70$  years.~~  
69 SMM was assessed by DEXA-scan and expressed as Appendicular Muscle Mass (ALM), LVM was  
70 estimated through echocardiography. Low ALM Sarcopenia was defined according to Foundation  
71 for the National Institutes of Health Sarcopenia Project (FNIH) criteria, and Short Physical  
72 Performance Battery (SPPB) was used to assess physical performance~~physical frailty basing on~~  
73 Short Physical Performance Battery (SPPB).

74 **RESULTS:** The population consisted of 100 persons (33 men and 67 women), aged  $\geq 70$  years  
75 (mean age  $79 \pm 5$ ) with low ALM and SPPB ranged between 3 and 9 suggestive of physical frailty.  
76 Charlson Comorbidity Index median score was 0. Mean values of LVM were  $193 \pm 67$  (g), indexed

77 LVM to body surface area (LVM/BSA) 112±33 (g/m<sup>2</sup>), and Cardiac Output (CO) 65±19 (l/min).  
78 Females showed significantly lower CO and higher ejection fraction (EF) compared to the male  
79 group. ALM was strongly and positively correlated with LVM ( $r=0.54602$ ,  $p<.0001$ ), LVM/BSA  
80 ( $r=0.30761$ ,  $p<0.002$ ), CO ( $r=0.49621$ ,  $p<.0001$ ), BMI ( $r=0.52461$ ,  $p<.0001$ ), sex ( $r=0.77$ ,  $p<0.001$ ),  
81 fat mass ( $r=0.38977$ ,  $p<0.0001$ ) and Hb ( $r=0.26001$ ,  $p<0.01$ ). ~~The population consisted of 100~~  
82 ~~persons (33 men and 67 women), aged  $\geq 70$  years with low ALM and SPPB ranged between 3 and 9~~  
83 ~~suggestive of physical frailty. Mean values of LVM were  $193 \pm 67$  (g), indexed LVM to body~~  
84 ~~surface area (LVM/BSA)  $112 \pm 33$  (g/m<sup>2</sup>), and Cardiac Output (CO)  $65 \pm 19$  (l/min). Females~~  
85 ~~showed significantly lower CO and higher EF compared to the male group. ALM was strongly and~~  
86 ~~positively correlated with LVM ( $r=0.54602$ ,  $p<.0001$ ), LVM/BSA ( $r=0.30761$ ,  $p<0.002$ ), CO~~  
87 ~~( $r=0.49621$ ,  $p<.0001$ ), BMI ( $r=0.52461$ ,  $p<.0001$ ), sex ( $r=0.77$ ,  $p<0.001$ ), FM ( $r=0.38977$ ,~~  
88  ~~$p<0.0001$ ) and Hb ( $r=0.26001$ ,  $p<0.01$ ).~~ In the multivariate analysis, LVM ( $\beta$  0.019±0.005;  
89  $p<0.0001$ ), CO ( $\beta$  0.038±0.016;  $p=0.019$ ), BMI ( $\beta$  0.286±-0.051;  $p <0.0001$ ) and Hb ( $\beta$  0.544 ±  
90 0.175;  $p=0.0025$ ) remained associated to ALM.

91 **CONCLUSIONS:** In a sample of older persons with low muscle mass and physical performance  
92 sarcopenia and physical frailty, LVM was positively and significantly correlated with ALM,  
93 independently from blood pressure, physical activity, and other potential confounders. Future  
94 studies are needed to address the effect of interventions targeting LVM and SMM.

95

96 **Key words:** skeletal muscle mass; left ventricular mass; low physical performance  
97 sarcopenia; frailty; SPRINTT study.

## 98 INTRODUCTION

99 ~~Current understanding between skeletal muscle mass and the heart is confined to literature that~~  
100 ~~describes alterations in skeletal muscle mass (SMM) and cardiovascular diseases.<sup>1-4</sup> In particular, in~~  
101 ~~patients with heart failure, either with a reduced or preserved ejection fraction, a loss of SMM~~  
102 ~~contributes to the onset of fatigue and exercise intolerance. However, much less is known about the~~  
103 ~~relationship between skeletal mass deficit, i.e., sarcopenia, and cardiac function and structure.~~

104 ~~Sarcopenia is considered a primarily age-dependent condition, characterized by the loss of SMM~~  
105 ~~and strength.~~ Sarcopenia is considered a primarily age-dependent condition, frequently overlapped  
106 with physical frailty.<sup>51</sup> The aforementioned condition is closely related to a level of physical  
107 impairment that can lead to disability. The flip side of this assertion is physical frailty,<sup>52</sup> a geriatric  
108 syndrome characterized by reduced homeostatic reserve. Both these ~~This conditions~~ exposes the  
109 subject to an increased risk of adverse negative events, ~~including and, as with sarcopenia, the risk~~  
110 of impaired physical function impairment and disability.<sup>62</sup>

111 Changes in skeletal muscle mass (SMM) have been associated with cardiovascular diseases.<sup>1-4,3-6</sup> In  
112 particular, in patients with heart failure, either with reduced or preserved ejection fraction, a loss of  
113 SMM contributes to the onset of fatigue and exercise intolerance. ~~Observational studies have also~~  
114 ~~evaluated the relationship between frailty and cardiac function and cardiovascular diseases.~~<sup>7-10</sup>

115 Patients with physical frailty have a higher prevalence of cardiovascular diseases such as myocardial  
116 infarction, angina, and congestive heart failure than well-performing patients.<sup>10</sup> Furthermore, in  
117 those patients without a history of cardiovascular disease, frailty was associated with subclinical  
118 heart disease i.e., left ventricular hypertrophy (LVH), which is considered a form of preclinical  
119 organ damage associated with systolic and diastolic dysfunction.<sup>7-9</sup> ~~These data support the~~  
120 ~~hypothesis that cardiovascular dysfunction plays an important role in the development of frailty and~~  
121 ~~suggests the importance of a cardiac evaluation in frail subjects.~~



122 Moreover, it has been demonstrated that, after bed rest or inactivity - well-known risk factors for  
123 sarcopenia and physical impairment and physical frailty- cardiac atrophy occurs in both men and  
124 women suggesting a common regulation of heart and muscle mass.<sup>11-13</sup>

125 All these data suggest Given the burden of physical disability with aging, the utmost important  
126 interaction of the identification of factors contributing to the development of sarcopenia and  
127 physical frailty with cardiac mass during aging is of utmost importance. The existence of cardiac-  
128 muscle axis has been recently hypothesized in older- Singapore Korean subjects where a se-positive  
129 and significant relationship was found between skeletal and cardiac ventricular mass.<sup>14-28</sup> Keng  
130 (ref). However this association was not independent of confounders frequently encountered in the  
131 real multimorbid determinants could influence not only the risk of disability but also affects heart  
132 structure and function and, as a consequence, the patients cardiovascular prognosis. Additionally,  
133 although low skeletal muscle mass is considered the other side of the coin, physical impairment  
134 physical frailty coin,<sup>2</sup> the combination of these conditions is not routinely assessed during daily  
135 clinical practice.

136 ==

137 However, Given the unique opportunity to assess a selected cohort of participants enrolled because  
138 of low ALM and score of SPPB short physical performance battery in the range between 3 and 9  
139 (proxy of physical frailty), we However, since no study has specifically explored the relationship  
140 between left ventricular mass (LVM; (independent variable) and SMM (dependent variable) in a  
141 group of individuals with these characteristics older people with sarcopenia and physical frailty, we  
142 tested this hypothesis in a group of individuals with these characteristics.

143

144

## 145 **METHODS**

146 Data are from an ancillary study of the Sarcopenia and Physical fRailty IN older people: multi-  
147 component Treatment strategies (SPRINT-T) project,<sup>145</sup> –a randomized control trial conducted in  
148 frail, sarcopenic older subjects aged 70 years and older, to demonstrate the effectiveness of a  
149 multicomponent (MCI) intervention based on physical activity, nutritional and technological  
150 intervention versus a healthy aging lifestyle education (HALE) program for the prevention of  
151 mobility disability.

152 Inclusion and Exclusion criteria for the Study were detailed elsewhere:<sup>16-</sup>

153 -Men and women aged  $\geq$  70 years;

154 -~~Short Physical Performance Battery (SPPB)~~ score between 3 (included) and 9 (included);

155 -Ability to complete the 400-m walk test within 15 min without sitting down, help from another  
156 person, use of a walker, or stopping for more than 1 minute at a time;

157 -Presence of low muscle mass according to results from a Dual Energy X-Ray Absorptiometry  
158 (DEXA) scan. In agreement with the ~~Foundation for the National Institutes of Health Sarcopenia  
159 Project (FNIH)~~ report 32, low muscle mass will be defined as: Body mass index-adjusted  
160 appendicular lean mass (AaLM; i.e., the sum of lean mass from both arms and legs):  $<0.789$  in men,  
161 and  $<0.512$  in women, OR ii. aALM  $<19.75$  kg in men and  $<15.02$  kg in women;

162 -Willingness to be randomised to either intervention group and to follow the study protocol.

163 Exclusion criteria:

164 -Unable or unwilling to provide informed consent or accept randomisation to either study group;

165 -Plans to relocate out of the study area within the next 2 years or plans to be out of the study area for  
166 more than 6 consecutive weeks in the next year;

167 -Residence in long-term care;

168 -Household member enrolled in the study;

169 -Current diagnosis of schizophrenia, other psychotic or bipolar disorder. Depression is not an  
170 exclusion criterion;

171 -Consumption of more than 14 alcoholic drinks per week;

- 172 -Difficulty communicating with the study personnel due to speech, language, or (noncorrected)  
173 hearing problems;
- 174 -Mini Mental State Examination (MMSE) lower than 24/30;
- 175 -Severe osteoarthritis (e.g., awaiting joint replacement) that would interfere with the ability to  
176 participate fully in either study arm;
- 177 -Cancer requiring treatment in the past 3 years, except for non-melanoma skin cancers or cancers  
178 that have an excellent prognosis (e.g., early stage breast or prostate cancer);
- 179 -Lung disease requiring regular use of supplemental oxygen;
- 180 -Inflammatory conditions requiring regular use of oral or parenteral corticosteroid agents;
- 181 -Severe cardiovascular disease (including New York Heart Association [NYHA] class III or IV.

182 The investigators of the Parma SPRINT-T<sup>-145-156</sup> site added, at the enrolment of participants, a  
183 complete cardiac assessment including clinical evaluation with 12-lead resting Electrocardiogram  
184 (ECG) and conventional and Doppler Tissue Echocardiographic (DTE) examination as part of the  
185 ancillary protocol to the enrolment of participants.

186 This ancillary study was submitted to SPRINT-T Scientific Committee and accepted by the  
187 Managing Entity, and subsequently approved by AVEN Local ethics committee (*Protocol n.10872*).  
188 Written informed consent was obtained from the participants.

189 One hundred subjects from those enrolled in the SPRINT-T study in the Frailty Clinic of the  
190 University-Hospital of Parma site were selected. Blood pressure (BP) and heart rate (HR) (OMRON  
191 705 IT) were assessed with three consecutive measurements, the data of which were averaged.

192 Level of physical activity (PA) was assessed by a questionnaire that included detailed information  
193 on type, intensity and duration of physical activity.<sup>-167</sup>

194 Whole-body ~~dual energy X-ray absorptiometry~~ (DEXA) scans were used to estimate SMM as  
195 ~~Appendicular Lean Muscle Mass~~ (ALM), and sarcopenia was defined according to the  
196 recommendation of the ~~Foundation for the National Institutes of Health~~ (FNIH) (ALM/BMI <0.789

197 in men and  $<0.512$  in women; and/or crude ALM  $<19.75$  Kg in men and  $<15.02$  Kg in women).<sup>178</sup>

198 Fat mass (FM) was also derived from DEXA and expressed in Kg.

199 Physical Frailty was assessed by ~~Short Physical Performance Battery (SPPB)~~, a battery of three  
200 tests with a score in the range between 3 and 9, and this was considered one of the eligibility  
201 criteria. Participants in the SPRINT-T trial needed to have sufficient cognitive abilities measured  
202 using ~~Mini Mental State Examination test (MMSE)~~, and those participants with MMSE  $> 24$  were  
203 included in the study.<sup>198</sup>

204 Charlson Comorbidity Index (CCI) Mean score was used to assess multimorbidity, the median score  
205 of CCI was estimated according to Charlson et al..<sup>20</sup>

206 M-mode, two-dimensional, and Doppler ECHO were performed by an ultrasonography-experienced  
207 cardiologist (GP), using a commercially available, multi-hertz sector, 2-4 MHz probe-equipped  
208 machine (Vivid S5, GE Healthcare, USA). The interventricular septal (SWT) and posterior (PWT)  
209 left ventricular (LV) wall thicknesses, systolic and diastolic (EDD) diameters and volumes, absolute  
210 LVM and indexed to body surface area (LVM/BSA) were calculated as previously described.<sup>1921</sup>

211 LVH was defined as LVM/BSA of  $>95\text{g}/\text{m}^2$  in women and  $>115\text{g}/\text{m}^2$  in men.<sup>220</sup> -Relative wall  
212 thickness (RWT) was calculated as:  $(\text{SWT}+\text{PWT})/\text{EDD}$ , using the 0.42 cut-off to define eccentric  
213 ( $\leq 0.42$ ) or concentric ( $>0.42$ ) remodelling.<sup>220</sup> Simpson's biplane rule-based end-diastolic (EDV)  
214 and systolic (ESV) volumes and ejection fraction (EF) were calculated, while Fractional Shortening  
215 (FS) was:  $[(\text{EDV} - \text{ESV})/\text{EDV}] \times 100$ . Cardiac output was derived by the formula:  $\text{EDV}-\text{ESV}$ .

216 Mitral inflow pattern was analysed from apical 4-chamber view, and E and A wave and their ratio  
217 were considered as peak flow velocity (pv) and time velocity integral (tvi), in order to evaluate the  
218 conventional diastolic function. From the same projection, DTE analysis was performed at lateral  
219 site and postero-septum of mitral annulus to assess myocardial systolic (S) and diastolic (E', A')  
220 waves of LV. The ratio of early diastolic mitral inflow velocity to early diastolic mitral annulus  
221 velocity (E/E' ratio) was calculated for the estimation of LV filling pressure.

222 DEXA scan and cardiological assessment were performed at baseline, within a temporal window of  
223 30 days.

224 Data are reported as means  $\pm$  SD or numbers and percentage. Factors statistically correlated with  
225 ALM, proxy of SMM, were identified using age- and sex-adjusted partial correlation coefficient  
226 and Spearman partial rank-order correlation coefficients, as appropriate. Parsimonious models  
227 obtained by backward selection from initial fully adjusted models, including age, BMI, systolic BP  
228 (SBP), HR, LVM, CO, level of physical activity PA, Hb, MMSE and beta-blockers or ACE-  
229 inhibitors/angiotensin receptor blockers, were used to identify independent factors of ALM. Sex  
230 was not included in the model because the collinearity between LVM and sex ( $R=0.51$ ,  $p<0.0001$ ).  
231 A 2-tailed  $p$  value  $<0.05$  was considered as statistically significant. SAS 8.2 statistical package was  
232 used for all analyses (SAS Institute, Inc., Cary, NC, USA).

233

234

## 235 **RESULTS**

236 Table 1 shows the main characteristics of the study population: 67 were women and 33 men (mean  
237 age was  $79\pm 5$  years). The mean BMI was ~~higher than~~  $27.6$   $\text{Kg/m}^2$  with one third of the sample  
238 having BMI value  $>30$   $\text{Kg/m}^2$ . CCI median score was 0, without significant differences between  
239 men and women. The mean SBP value was  $138\pm 18$   $\text{mmHg}$  ~~high normal~~ and 70% had a history of  
240 hypertension; 12% had coronary artery disease, and 3% had significant cardiac valve disease. No  
241 sign of heart failure was detected in any of the patients. With regard to the other comorbidities of  
242 the sample, thyroid diseases were reported in 20% and diabetes mellitus in 9%. Forty-one percent  
243 of the participants were chronically on  $\beta$ -blockers, 32% on ACE-inhibitors, and 21% on  
244 Angiotensin II Receptor Blockers (ARB). Mean values of ALM crude and ALM/BMI and indexed  
245 by BMI and SPPB were consistent with the eligibility criteria adopted in SPRINT-T for defining a  
246 sarcopenic and physically frail population (Table 1).

247 The thicknesses of SWT and PW and the LV cavity size, as assessed by diameters and volumes,  
248 were in the normal range with males exhibiting greater LV thicknesses and dimensions compared  
249 with females ([Supplementary Table 2](#)). Both LVM and LVM/BSA were higher in men and  
250 women, especially in older and hypertensive subjects with a tendency to a geometric remodelling,  
251 as evaluated by RWT in both groups ([Supplementary Table 2](#)).

252 LV systolic function, assessed by EF and FS, was in the normal range as well as CO in the total  
253 population, with females showing significantly lower CO and higher EF compared to the male  
254 group ([Supplementary Table 2](#)). The mitral inflow pattern showed significant reduction of the E/A  
255 ratios in these patients, suggesting an impaired relaxation, –confirmed by a lower E' wave from  
256 DTE-analysis–, which also demonstrated a reduction of S wave without significant differences  
257 between the male and female groups ([Supplementary Table 2](#)). E/E' excluded an increased LV  
258 filling pressure in our cohort.

259 ALM was strongly and positively correlated with LVM ( $r=0.54602$ ,  $p<.0001$ ), LVM/BSA  
260 ( $r=0.30761$ ,  $p<0.002$ ), CO ( $r=0.49621$ ,  $p<.0001$ ), but also with other structural cardiac parameters  
261 such as LV thicknesses, diameters, and volumes (Table 23). In addition, factors associated to ALM  
262 included BMI ( $r=0.52461$ ,  $p<.0001$ ), sex ( $r=0.77$ ,  $p<0.001$ ), FM ( $r=0.38977$ ,  $p<0.0001$ ) and Hb  
263 ( $r=0.26001$ ,  $p<0.01$ ) (Table 23). A negative association was detected between ALM and EF ( $r=-$   
264  $0.30$ ,  $p<.0001$ ) and FS ( $r=-0.27$ ,  $p<.001$ ), whilst no significant correlation was found with S wave  
265 and all diastolic parameters (E/A, E' wave and E/E'). Multivariate analysis confirmed as factors  
266 independently associated to ALM, only LVM ( $\beta 0.019\pm 0.005$ ;  $p<0.0001$ ), CO ( $\beta 0.038\pm 0.016$ ;  
267  $p=0.019$ ), BMI ( $\beta 0.286 \pm 0.051$ ;  $p<0.0001$ ) and Hb ( $\beta 0.544 \pm 0.175$ ;  $p=0.0025$ ) (Table 34). Age,  
268 SBP, HR, levels of physical activity PA, pharmacological therapy, and MMSE were not  
269 significantly associated with ALM.

270

271

272

273  
274  
275  
276  
277  
278

## 279 **DISCUSSION**

280 Main results of the present study are the significant correlations between ALM, proxy of SMM, and  
281 LVM in ~~frail and sarcopenic~~ older adults with low skeletal muscle mass and physical performance,  
282 independently by confounders. ALM was also associated with cardiac output, independently of  
283 LVM.

284 This relationship is not surprising. S~~Both sarcopenia and cardiovascular disease shares with~~  
285 cardiovascular disease ~~common~~ risk factors, such as age, sedentary lifestyle, obesity, insulin  
286 resistance, and metabolic syndrome.<sup>213,224</sup> ~~Sarcopenia is also associated with an increased risk of~~  
287 ~~cardiovascular diseases, as reported by the KNHANES survey.~~<sup>253</sup>

288 Recent studies have also shown that sarcopenia is strictly and independently associated with  
289 ~~indicators of atherosclerosis (such as stiffness, PWV and intima-media thickness, alls) that are~~ risk  
290 factors of cardiovascular disease.<sup>246</sup> ~~Our results suggest that both cardiac and skeletal muscle are~~  
291 ~~associated and potentially share the same contributors.~~

292 The link between the cardiac disease and SMM is well-established in heart failure patients who  
293 develop secondary sarcopenia due to heart disease.<sup>3-61-4</sup> ~~In this context, the SMM loss can be~~  
294 ~~attributed to R~~reduced blood oxygenation, physical inactivity and associated increase of  
295 inflammatory markers, may induce damage in that can damage both SMM and cardiac muscle  
296 mass.<sup>3-61-4</sup>

297 ~~Morphological, histological, biochemical, metabolic and energetic analyses, conducted on muscle~~  
298 ~~biopsies, electromyography, spectroscopy and magnetic resonance imaging have shown that in~~



299 ~~chronic heart failure the early onset of fatigue and intolerance to exercise was attributable to a shift~~  
300 ~~from an aerobic to anaerobic metabolism at the muscle level.~~

301 There are indeed few studies on the relationship between skeletal muscle disease, sarcopenia, and  
302 cardiac structure and function. We studied this relationship in a specific population ~~off frail and~~  
303 ~~sarcopenic~~ older persons selected because of low muscle mass and physical performance.

304 Interestingly, we found a strong positive association between ALM and LVM and CO (functional  
305 and hemodynamic parameter), also independently of LVM (structural cardiac parameter) -i.e. more  
306 skeletal mass, more LVM and CO.

307 Our data are consistent with Keng et coworkers ~~that~~who recently demonstrated, among a large  
308 study sample of Asian older adults without cardiovascular disease, that sarcopenic participants  
309 (n=88 subjects aged 74) had smaller LV cavity size and mass than not sarcopenic ones, suggesting  
310 the presence of cardio-sarcopenia syndrome.<sup>2147</sup> We confirmed this concept here in a different more  
311 characterized population (European vs Asian) of older ~~sarcopenic and physical frail~~ individuals  
312 using a ~~Importantly, a~~ more robust technique of DEXA (instead of bioimpedance) was used in our  
313 study to assess body composition.

314 These results are not in agreement with those presented in two previous studies.<sup>275,268</sup> -The first  
315 study, conducted in a population of Koreans with an average age of 58 years enrolled in an  
316 epidemiological study, showed that high visceral adiposity and low skeletal muscle mass were  
317 independent predictors of LVM.<sup>257</sup> -However, the participants of this study were not classified  
318 according to sarcopenic status and were relatively young.

319 The second study, realized in a very large cohort of Korean adults (n=67,106), showed an increased  
320 prevalence of both diastolic dysfunction and LVH in the lowest skeletal muscle mass quartile.<sup>268</sup> -In  
321 our cohort, ALM was positively correlated with LVM, and did not correlate with all diastolic  
322 indexes such as E/A, E' wave and E/E'. The different results can be explained by the fact that  
323 However, in the Korean study<sup>286</sup>, -70.7% of population attributed to Q1 group were obese (vs  
324 39.0%, 20.7 and 7.1 in Q2, Q3 and Q4 respectively) with a higher proportion of hypertensive



325 (23.1% vs 14.8, 11.6 and 7.7 in Q2, Q3 and Q4 respectively) and diabetic (8.4% vs 5.5, 3.8 and 2.5  
326 in Q2, Q3 and Q4 respectively), – well known factors that potentially influence negatively the  
327 diastolic function. – ~~These data can justify the different results between our and Korean study.~~

328 ~~However,~~ Our study is also different from the studies aforementioned ~~previous studies~~ for many  
329 reasons: the age of the population, ethnicity (Caucasian vs. Asian), and the homogeneity of our  
330 sample population, which included only ~~frail and sarcopenic~~ older subjects with low SMM and  
331 physical performance.

332 ~~Keng et coworkers recently demonstrated, among a large study sample of Asian older adults~~  
333 ~~without cardiovascular disease, that sarcopenic participants (n=88 subjects aged 74) had smaller LV~~  
334 ~~cavity size and mass than not sarcopenic, suggesting the presence of cardio-sarcopenia syndrome.<sup>27</sup>~~

335 ~~We confirmed this concept here in a different more characterized population (European vs Asian) of~~  
336 ~~older sarcopenic and physical frail individuals. Importantly, a more robust technique of DXA~~  
337 ~~(instead of bioimpedance) was used in our study to assess body composition.~~

338 We should also consider that hHigh ~~The positive relationship between ALM and LVM is~~  
339 traditionally can be viewed as clinically unfavourable ~~phenomenon.~~ ~~This datum is somewhat of a~~  
340 ~~paradox because it is well known that~~ and LVH in hypertensive pathology is associated with  
341 ~~implies~~ greater CV risk and poorer prognosis.<sup>29,28</sup> ~~—The higher incidence of CV, mainly coronary~~  
342 ~~events due to LVH-related events,~~ is justified by the imbalance between increased consumption and  
343 insufficient O2 intake available for ~~due to~~ increased demand.

344  
345 Conversely, ~~However,~~ it should be also underlined the potential role of ~~LVH should be interpreted~~  
346 ~~not only as an energy expenditure but also considered~~ as a secondary compensatory mechanism  
347 adopted for increasing cardiac work. Examples in this regard include the physiological LVH of the  
348 athlete, i.e., the athlete's heart, ~~induced by regular exercise,~~ or pathological LVH ~~secondary to CV~~

349 ~~diseases, such as what occurings~~ with the hypertensive heart or ~~in cases of~~ aortic  
350 stenosis.<sup>2929,30030,31</sup>

351 While pPhysiological LVH allows an increase in cardiac output during sports performance, ~~while~~  
352 the pathological LVH ensures the maintenance of a normal cardiac throw, despite the increased  
353 after-load.<sup>30</sup>~~Therefore, pathological LVH is a positive functional adaptation mechanism in which~~  
354 ~~the heart reshapes itself into a condition capable of normalizing stress and maintaining stroke~~  
355 ~~volume.~~<sup>2930</sup>

356 ~~It is also well known that~~ Ppathological LVH, in contrast to the physiological one, is associated  
357 with both diastolic and systolic dysfunction, which can be highlighted not with conventional  
358 functional indices, such as EF and FS, but with more sophisticated techniques such as DTE and  
359 Strain.<sup>3121,3223</sup>

360 Consistently, in our study, ALM positively correlated with ~~CO~~cardiac output, and this relationship  
361 was also ~~maintained~~confirmed in by the multivariate analysis, including LVM as covariate. ~~We~~  
362 ~~cannot exclude that the relationship between exposure and outcome (LVM and SMM) could have~~  
363 ~~been influenced by -multimorbidity. In our study sample, there were patients who had heart disease~~  
364 ~~such as CAD, cardiac valve disease, as well as chronic conditions such as hypertension, COPD and~~  
365 ~~thyroid disease. In total, these conditions may account for at least 40% of the study sample. In~~  
366 ~~particular, the increased systolic BP and the high prevalence of hypertensive subjects (70%), could~~  
367 ~~have contributed to increase LV mass; however, this hypothesis was not confirmed in the~~  
368 ~~multivariate analysis.~~

369 Moreover, to better clarify the role of multimorbidity, we calculated- crude ~~Charlson Comorbidity~~  
370 ~~Index~~CCI whose median score of 0 (not surprising ~~—given the stricted exclusion criteria~~  
371 ~~aforementioned), we evaluated the relationship between CCI and ALM, and the role of CCI in the~~  
372 ~~association between ALM and LVM in the multivariate analysis.~~

373 ~~CCI median score~~enbasing on these data, ~~w~~moCCIALMCCI-CCI was not a significant predictor of  
374 ~~ALM (r=-0.12, p=0.22) -and -the introduction of~~ ~~Charlson Comorbidity Index~~CCI in the Backward

375 Analysis did not change the significant relationship between -ALM and LVM. Basing on this data,  
376 we can assume that multimorbidity had not a relevant impact in this specific sample.

377 ~~Skeletal muscle and heart muscle have many points in common. Both are streaky and composed of~~  
378 ~~sarcoma units, albeit with different characteristics and functions. They have the same embryonic~~  
379 ~~origin, both derived from mesoderm; the heart shares with SMM a large number of genes, mainly~~  
380 ~~those regulating the transcription of contractile and mitochondrial proteins.<sup>343,345</sup> The high number~~  
381 ~~of mitochondria, an expression of high oxidative capacity, testifies to a predominantly aerobic~~  
382 ~~metabolism of these two organs.<sup>354</sup>~~

383 ~~The size of these organs depends on anthropometric characteristics (height, weight and body~~  
384 ~~surface), sex, genetic makeup, and ethnicity.<sup>19, 35-38</sup> The most cardiac and muscular hypertrophy~~  
385 ~~among people of African ethnicity vs. Caucasian ethnicity are examples.<sup>36-39</sup> However, SMM is the~~  
386 ~~force of gravity, while the heart is governed by blood pressure.<sup>40</sup>~~

387 ~~The main strength of this study is the homogeneous sample of frail and sarcopenic older persons~~  
388 ~~enrolled in the study. Furthermore, the echocardiographic examinations were performed by a single,~~  
389 ~~experienced operator to limit the variability of the calculation of the LVM -- a measure that is~~  
390 ~~affected by both the quality of the images and the experience of the operator.~~

391 We should acknowledge that our study has two main limitations including may be the limited  
392 number of subjects enrolled and the cross-sectional nature of this study that does not allow to  
393 drawdrawingown conclusions about the nature of the relationship. Moreover, given the strict  
394 inclusion criteria and the cohort precisely defined features, the generalization of results for the  
395 entire population of the community of older adults deserves further investigation. Additionally,  
396 given the collinearity between sex and LVM, we cannot exclude an independent role of sex in  
397 determining ALM values. This should be verified in separate groups of males and females with a  
398 wider range of ALM values. The relatively low simple size of our group and the narrow dispersion  
399 of ALM in both males and females cannot permit such an analysis and therefore it should be  
400 considered as a major limitation of the study.

401 However, ~~these limitations are offset by important strengths. to our knowledge, T~~this is the first  
402 time a study investigates the relationship between ALM and LVM in a homogeneous group of both  
403 low frail and sarcopenic older people. muscle mass and physical performance. Furthermore, the  
404 echocardiographic examinations were performed by a single, experienced operator to limit the  
405 variability of the calculation of the LVM - a measure that is affected by both the quality of the  
406 images and the experience of the operator.

407 Moreover, ~~given the strict inclusion criteria and the cohort precisely defined features, the~~  
408 ~~generalization of results for the entire population of the community of older adults deserves~~  
409 ~~further investigation.~~

410 Since there was collinearity between sex and LVM, we cannot exclude an independent role of sex  
411 in determining ALM values. This should be verified in separate groups of males and females with  
412 a wider range of ALM values. The relatively low sample size of our group and the narrow  
413 dispersion of ALM in both males and females cannot permit such an analysis and therefore it  
414 should be considered as a major limitation of the study.

415 ~~The increased systolic BP and the high prevalence of hypertensive subjects (70%), related to CV~~  
416 ~~aging process, could have contributed to increase LV mass; however, SBP did not influence the~~  
417 ~~relationship between ALM and LVM in the multivariate analysis.~~

418 In our study we could not demonstrate the existence of other mechanisms to explain the relationship  
419 between the muscle heart and SMM. It is well known that SMM has paracrine and endocrine  
420 activity that releases modulators for the heart but also for the brain, liver, pancreas, bone and fatty  
421 tissue.<sup>41</sup> However, we did not have data on follistatin like 1 (TSTL1), apelin, musclin, fibroblast  
422 growth factor 21 (FGF-21), factors released by SMM and exerting beneficial effects on CV system  
423 in terms of cardioprotection, vascularization, and optimization of blood pressure.<sup>42</sup>

424 The available biobank of SPRINT-T will allow to measure biomarkers and to perform future  
425 analyses to test these interesting hypotheses.

426 In conclusion, the present study is the first one that demonstrates a highly significant and positive  
427 relationship between ALM and LVM in a ~~frail and sarcopenic cohort of~~ cohort of older adults with  
428 low muscle mass and physical performance. Our novel findings -emphasize the need of studying  
429 skeletal and heart in tandem -to better address -the -complexity of aging process.

430

## 431 **ACKNOWLEDGEMENTS**

432 The authors would like to acknowledge Dr. Karen Elena Brothers, who critically revised the  
433 manuscript.

434 **Financial Disclosure:** The present work was funded by a grant from the Innovative Medicines  
435 Initiative - Joint Undertaking (IMI-JU 115621).

436 **Conflicts of interest:** None declared

437 **Author contributions:** GP, FL and MM contributed to the conception and design of the work. All  
438 authors contributed to the acquisition, analysis, or interpretation of data for the work. GP performed  
439 all echocardiographic examinations and drafted the manuscript. All authors critically revised the  
440 manuscript and gave final approval.

441 **Sponsor's role:** Some authors of the present work are partners of the SPRINTT consortium, which  
442 is partly funded by the European Federation of Pharmaceutical Industries and Associations  
443 (EFPIA).

444

445

446

## 447 **REFERENCES**

448 1. Cruz-Jentoft AJ, Bahat G, Bauer J, et al Sarcopenia: revised European consensus on  
449 definition and diagnosis. Age Ageing 2019;48(1):16–31. doi:10.1093/ageing/afy169.

- 450 [2. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two](#)  
451 [sides of the same coin. Front Aging Neurosci 2014;6:192. doi:10.3389/fnagi.2014.00192.](#)
- 452 ~~1.3.~~ Saitoh M, Ishida J, Doehner W, et al. Sarcopenia, cachexia, and muscle performance  
453 in heart failure: Review update 2016. Int J Cardiol 2017;238:5–11.  
454 doi:10.1016/j.ijcard.2017.03.155.
- 455 ~~2.4.~~ Adams V, Linke A, Winzer E. Skeletal muscle alterations in HFrEF vs. HFpEF. Curr  
456 Heart Fail Rep 2017;14:489-497. doi:10.1007/s11897-017-0361-9.
- 457 ~~3.5.~~ Okita K, Kinugawa S, Tsutsui H. Exercise intolerance in chronic heart failure-  
458 skeletal muscle dysfunction and potential therapies. Circ J 2013;77(2):293-300.  
459 doi:10.1253/circj.cj-12-123.
- 460 ~~4.6.~~ Seiler M, Bowen T S, Rolim N, et al. Skeletal Muscle Alterations Are Exacerbated in  
461 Heart Failure With Reduced Compared With Preserved Ejection Fraction: Mediated by  
462 Circulating Cytokines? Circ Heart Fail 2016;9(9):e003027.  
463 doi:10.1161/CIRCHEARTFAILURE.116.003027.
- 464 ~~5. Cruz-Jentoft AJ, Bahat G, Bauer J, et al Sarcopenia: revised European consensus on~~  
465 ~~definition and diagnosis. Age Ageing 2019;48(1):16–31. doi:10.1093/ageing/afy169.~~
- 466 ~~6. Cesari M, Landi F, Vellas B, Bernabei R, Marzetti E. Sarcopenia and physical frailty: two~~  
467 ~~sides of the same coin. Front Aging Neurosci 2014;6:192. doi:10.3389/fnagi.2014.00192.~~
- 468 7. Gharacholou SM, Tashiro T, Cha SS, Scott CG, Takahashi PY, Pellikka PA.  
469 Echocardiographic indices associated with frailty in adults  $\geq 65$  years. Am J Cardiol  
470 2015;116(10):1591–1595. doi:10.1016/j.amjcard.2015.08.023.
- 471 8. Leibowitz D, Jacobs JM, Gilon D, Lande-Stessman I, Ein-Mor E, Stessman J. Cardiac  
472 Structure and Function and Frailty in Subjects Aged 85 and 86 Years. Am J Cardiol  
473 2016;118(5):760–764. doi:10.1016/j.amjcard.2016.06.005.

- 474 9. Nadruz W, Jr, Kitzman D, Windham B G, et al. Cardiovascular Dysfunction and Frailty  
475 Among Older Adults in the Community: The ARIC Study. *J Gerontol A Biol Sci Med Sci*  
476 2017;72(7):958–964. doi:10.1093/gerona/glw199.
- 477 10. Veronese N, Cereda E, Stubbs B, et al. Risk of cardiovascular disease morbidity and  
478 mortality in frail and pre-frail older adults: Results from a meta-analysis and exploratory  
479 meta-regression analysis. *Ageing Res Rev* 2017;35:63–73. doi:10.1016/j.arr.2017.01.003.
- 480 11. Kortebein P, Ferrando A, Lombeida J, Wolfe R, Evans WJ. Effect of 10 days of bed rest on  
481 skeletal muscle in healthy older adults. *JAMA* 2007;297(16):1772–1774.  
482 doi:10.1001/jama.297.16.1772-b.
- 483 12. Perhonen M A, Franco F, Lane LD, et al. Cardiac atrophy after bed rest and spaceflight. *J*  
484 *Appl Physiol* 2001;91(2):645–653. doi:10.1152/jappl.2001.91.2.645.
- 485 13. Dorfman T A, Levine BD, Tillery T, et al. Cardiac atrophy in women following bed rest. *J*  
486 *Appl Physiol* 2007;103(1):8–16. doi:10.1152/jappphysiol.01162.2006.
- 487 14. Keng BMH, Gao F, Teo LLY, et al. Associations between Skeletal Muscle and Myocardium  
488 in aging: A syndrome of “Cardio-Sarcopenia”? *J Am Geriatr Soc* 2019;67:2568-2573.  
489 doi:10.1111/jgs.16132.
- 490 14:15. Marzetti E, Cesari M, Calvani R, et al. The "Sarcopenia and Physical fRaily IN  
491 older people: multi-component Treatment strategies" (SPRINTT) randomized controlled  
492 trial: Case finding, screening and characteristics of eligible participants. *Exp Gerontol*  
493 2018;113:48–57. doi:10.1016/j.exger.2018.09.017.
- 494 15:16. Landi F, Cesari M, Calvani R, et al. The "Sarcopenia and Physical fRaily IN older  
495 people: multi-component Treatment strategies" (SPRINTT) randomized controlled trial:  
496 design and methods. *Aging Clin Exp Res* 2017;29(1):89–100. doi:10.1007/s40520-016-  
497 0715-2.

- 498 ~~16-17.~~ Wareham NJ, Jakes RW, Rennie KL, Mitchell J, Hennings S, Day NE. Validity and  
499 repeatability of the EPIC-Norfolk Physical Activity Questionnaire. *Int J Epidemiol*  
500 2002;31:168–174. doi: 10.1093/ije/31.1.168.
- 501 ~~17-18.~~ Studenski SA, Peters KW, Alley DE, et al. The FNIH sarcopenia project: rationale,  
502 study description, conference recommendations, and final estimates. *J Gerontol A Biol Sci*  
503 *Med Sci* 2014;69(5):547–558. doi:10.1093/gerona/glu010.
- 504 19. Longobucco Y, Benedetti C, Tagliaferri S, et al. Proactive interception and care of Frailty  
505 and Multimorbidity in older persons: the experience of the European Innovation Partnership  
506 on Active and Healthy Ageing and the response of Parma Local Health Trust and Lab  
507 through European Projects. *Acta Biomed* 2019;90(2):364–374.  
508 doi:10.23750/abm.v90i2.8419.
- 509 ~~18-20.~~ Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic  
510 comorbidity in longitudinal studies: development and validation. *J Chronic Dis.*  
511 1987;40(5):373-383. doi:10.1016/0021-9681(87)90171-8.
- 512 ~~19-21.~~ Pelà G, Crocamo A, Li Calzi M, et al. Sex-related differences in left ventricular  
513 structure in early adolescent non-professional athletes. *Eur J Prev Cardiol* 2016;23(7):777–  
514 784. doi:10.1177/2047487315608826.
- 515 ~~20-22.~~ Lang RM, Bierig M, Devereux RB, et al. Recommendations for chamber  
516 quantification. *Eur J Echocardiogr* 2006;7(2):79–108. doi:10.1016/j.euje.2005.12.014.
- 517 ~~21-23.~~ Kang DO, Park SY, Choi BG, et al. Prognostic Impact of Low Skeletal Muscle Mass  
518 on Major Adverse Cardiovascular Events in Coronary Artery Disease: A Propensity Score-  
519 Matched Analysis of a Single Center All-Comer Cohort. *J Clin Med.* 2019;8(5):712.  
520 doi:10.3390/jcm8050712.
- 521 ~~22-24.~~ Bahat G, Ilhan B. Sarcopenia and cardiometabolic syndrome: A narrative review.  
522 *Eur Geriatric Med* 2016;7(3):220-223. doi:10.1016/j.eurger.2015.12.012..



- 523 [23-25.](#) Bieon CH, Kang KY, Kang SH, NiBae EJ. Sarcopenia is associated with  
524 Framingham risk score in the Korean population: Korean National Health and Nutrition  
525 examination survey (KNHANES). *J Geriatr Cardiol* 2015;12:366-372.  
526 doi:10.11909/j.issn.1671-5411.2015.04.007.
- 527 [24-26.](#) Ochi M, Kohara K, Tabara Y, et al. Arterial Stiffness is associated with low thigh  
528 muscle mass in middle-aged to elderly men. *Atherosclerosis* 2010;212(1):327–332.  
529 doi:10.1016/j.atherosclerosis.2010.05.026.
- 530 [25-27.](#) Park J, Kim NH, Kim SH, et al. Visceral adiposity and skeletal muscle mass are  
531 independently and synergistically associated with left ventricular structure and function: The  
532 Korean Genome and Epidemiology Study. *Int J Cardiol* 2014;176(3):951–955.  
533 doi:10.1016/j.ijcard.2014.08.108.
- 534 [26-28.](#) Ko BJ, Chang Y, Kang JG, et al. Low relative muscle mass and left ventricular  
535 diastolic dysfunction in middle-aged adults. *Int J Cardiol* 2018;255:118–123.  
536 doi:10.1016/j.ijcard.2017.07.089.
- 537 ~~27. Keng BMH, Gao F, Teo LLY, et al. Associations between Skeletal Muscle and Myocardium~~  
538 ~~in aging: A syndrome of “Cardio-Sarcopenia”? *J Am Geriatr Soc* 2019;67:2568-~~  
539 ~~2573. doi:10.1111/jgs.16132.~~
- 540 [28-29.](#) Levy D, Garrison RJ, Savage DD, Kannel WB. & Castelli WP. Prognostic  
541 Implications Of Echocardiographically Determined Left Ventricular Mass In The  
542 Framingham Heart Study. *N Engl J Med* 1990;322(22):1561–1566.  
543 doi:10.1056/NEJM199005313222203.
- 544 [29-30.](#) Lovic D, Narayan P, Pittaras A, Faselis C, Doulas M, Kokkinos P. Left ventricular  
545 hypertrophy in athletes and hypertensive patients. *J Clin Hypertens* 2017;19(4):413-417.  
546 doi:10.1056/NEJM199005313222203.

- 547 [31.](#) Rader F, Sachdev E, Arsanjani R, Siegel RJ. Left ventricular hypertrophy in valvular aortic  
548 stenosis: mechanisms and clinical implications. *Am J Med* 2015;128(4):344-352.  
549 doi:10.1016/j.amjmed.2014.10.054.
- 550 ~~30.~~
- 551 ~~31.32.~~ Pelà G, Bruschi G, Montagna L, Manara M, Manca C. Left and right ventricular  
552 adaptation assessed by Doppler tissue echocardiography in athletes. *J Am Soc Echocardiogr*  
553 2004;17(3):205–211. doi:10.1016/j.echo.2003.12.004.
- 554 ~~32.33.~~ Pelà G, Bruschi G, Cavatorta A, Manca C, Cabassi A, Borghetti A. Doppler tissue  
555 echocardiography: myocardial wall motion velocities in essential hypertension. *Eur J*  
556 *Echocardiogr* 2001;2(2):108–117. doi:10.1053/euje.2000.0057.
- 557 ~~33.~~ Boengler K, Kosiol M, Mayr M, Schulz R, Rohrbach S. Mitochondria and ageing: role in  
558 heart, skeletal muscle and adipose tissue. *J Cachexia Sarcopenia Muscle* 2017;8(3):349–369.  
559 doi:10.1002/jesm.12178.
- 560 ~~34.~~ Lindskog C, Linné J, Fagerberg L, et al. The Human cardiac and Skeletal Muscle Proteomes  
561 defined by transcriptomics and antibody-based profiling. *BMC Genomics* 2015;16(1):475.  
562 doi:10.1186/s12864-015-1686-y.
- 563 ~~35.~~ de Simone G, Devereux RB, Daniels SR, & Meyer RA. Gender differences in left  
564 ventricular Growth. *Hypertension* 1995;26(6 Pt 1):979–983. doi:10.1161/01.hyp.26.6.979.
- 565 ~~36.~~ Drazner MH, Dries DL, Peshock RM, et al. Left ventricular hypertrophy is more prevalent  
566 in blacks than in whites in the general population: The Dallas Heart Study. *Hypertension*  
567 2005;46(1):124–129. doi:10.1161/01.HYP.0000169972.96201.8e.
- 568 ~~37.~~ Araujo AB, Chiu GR, Kupelian V, et al. Lean mass, muscle strength, and physical function  
569 in a diverse population of men: a population-based cross-sectional study. *BMC Public Health*  
570 2010;10:508. doi:10.1186/1471-2458-10-508.

- 571 38. Pelà G, Li Calzi M, Crocamo A, et al. Ethnicity-related variations of left ventricular  
572 remodeling in adolescent amateur football players. *Scand J Med Sci Sports* 2015;25(3):382-389.  
573 doi:10.1111/sms.12238.
- 574 39. Demola P, Crocamo A, Ceriello L, et al. Hemodynamic and ECG responses to stress test in  
575 early adolescent athletes explain ethnicity-related cardiac differences. *Int J Cardiol* 2019;289:125-  
576 130. doi:10.1016/j.ijcard.2019.04.084.
- 577 40. de Simone G, Devereux RB, Kimball TR, et al. Interaction between body size and cardiac  
578 workload. Influence on left ventricular mass during body growth and adulthood. *Hypertension*  
579 1998;31(5):1077-1082. doi:10.1161/01.hyp.31.5.1077.
- 580 41. Giudice J, & Taylor JM. Muscle as a paracrine and endocrine organ. *Curr Opin Pharmacol*  
581 2017;34:49-55. doi:10.1016/j.coph.2017.05.005.
- 582 Morley JE. Hormones and Sarcopenia. *Curr Pharm Des* 2017;23(30):4484-4492.  
583 doi:10.2174/1381612823666161123150032. **FIGURE LEGEND**

584 Figure 1 is depicting the correlation between crude value of ALM and LVM (age- and sex-adjusted  
585 model).

586 \_

587

588 42.